They also have a life expectancy of 79.1 years, are significantly less likely to attend routine health screenings, are more likely to delay seeking medical attention for concerning symptoms, and face higher rates of cardiovascular disease, type 2 diabetes, liver disease, and suicide
These advanced medications are FDA-approved for obesity, helping patients achieve and sustain meaningful change when lifestyle changes alone fall short
Patients enrolled in the PIONEER 2 [15], PIONEER 3 [16], SUSTAIN 2 [17], and SUSTAIN 8 [18] trials had type 2 diabetes that was uncontrolled by metformin (with or without sulfonylurea) and were treated with an additional oral/subcutaneous GLP-1RA (semaglutide), oral SGLT-2i (empagliflozin/canagliflozin), or oral DDP-4i (sitagliptin)
A few sensitive skin users reported itching or acne